RE:Cantargia"Cantargia previously entered a collaboration with the Pancreatic Cancer Action Network (PanCAN) with the ambition to include nadunolimab in PanCAN’s adaptive phase II/III trial Precision Promise. While Cantargia’s partnership with PanCAN will continue, the two have agreed to put on hold nadunolimab’s potential participation in Precision Promise until results from the new phase IIb trial are available."
https://cantargia.com/en/press-releases/cantargia-intensifies-development-of-nadunolimab-in-pancreatic-cancer-with-new-controlled-phase-iib-clinical-trial-following-strong-phase-iia-efficacy-results